Chiasma Inc. (CHMA) Downgraded to Sell at Zacks Investment Research
According to Zacks, “Chiasma, Inc. is a biopharmaceutical company. The company’s TPE(R) technology develops oral peptides and other molecules. Its primary product candidate consists of oral octreotide which is in different clinical trial. Chiasma, Inc. is based in Newton, USA. “
Shares of Chiasma (NASDAQ:CHMA) opened at 3.00 on Tuesday. The firm’s market cap is $73.07 million. Chiasma has a 52 week low of $2.40 and a 52 week high of $24.78. The firm’s 50-day moving average is $2.76 and its 200 day moving average is $3.70.
Chiasma (NASDAQ:CHMA) last issued its quarterly earnings data on Wednesday, August 10th. The company reported ($1.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by $0.47. Equities research analysts forecast that Chiasma will post ($3.14) EPS for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the company. Opaleye Management Inc. purchased a new position in shares of Chiasma during the first quarter valued at approximately $183,000. A.R.T. Advisors LLC purchased a new position in shares of Chiasma during the second quarter valued at approximately $441,000. Geode Capital Management LLC raised its position in shares of Chiasma by 19.4% in the first quarter. Geode Capital Management LLC now owns 55,693 shares of the company’s stock valued at $510,000 after buying an additional 9,038 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Chiasma by 25.7% in the second quarter. Vanguard Group Inc. now owns 426,477 shares of the company’s stock valued at $1,233,000 after buying an additional 87,259 shares during the last quarter. Finally, Sphera Funds Management LTD. purchased a new position in shares of Chiasma during the first quarter valued at approximately $2,113,000. Institutional investors own 58.76% of the company’s stock.
Chiasma Company Profile
Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.
Receive News & Stock Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related stocks with our FREE daily email newsletter.